Altered IFNγ signaling and preserved susceptibility to activated natural killer cell-mediated lysis of BCR/ABL targets

Cancer Research

Volumn 65, Issue 7, 2005, Pages 2914-2920

  Cebo, Christelle ^a   Voutsadakis, Ioannis A ^a   Da Rocha, Sylvie ^a   Bourhis, Jean Henri ^a   Jalil, Abdelali ^a   Azzarone, Bruno ^b   Turhan, Ali G ^a   Chelbi Alix, Mounira ^c   Chouaib, Salem ^a   Caignard, Anne ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c Laboratory of Viral Oncology   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; IMATINIB; INTERFERON REGULATORY FACTOR 1; STAT1 PROTEIN; ALPHA INTERFERON; HLA ANTIGEN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADOPTIVE TRANSFER; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SUSCEPTIBILITY; CELL MEDIATED LYMPHOLYSIS; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; NATURAL KILLER CELL; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TARGET CELL DESTRUCTION; ADOPTIVE IMMUNOTHERAPY; BIOSYNTHESIS; BLOOD; CELL NUCLEUS; CYTOLOGY; GENETICS; HEMATOPOIETIC STEM CELL; IMMUNOLOGY; METABOLISM; PHYSIOLOGY;

CELL NUCLEUS; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELLS; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; INTERFERON-ALPHA; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PYRIMIDINES; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 16844383633     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1932     Document Type: Article

References (32)

1. Melo JG. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 2003;349:1451-64.
2. Druker B, Talpaz M, Resta D, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
3. Druker B, Sawyers C, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
4. Kantarjian H, Cortes J, O'Brien S, et al. Imatinib mesylate therapy in newly-diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2002;99:3547-53.
5. Sawyers C, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-9.
6. Margolis J, Borrello I, Flinn I. New approaches to treating malignances with stem cell transplantation. Semin Oncol 2000;27:524-30.
7. Luznik L, Fuchs E. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control 2002;9:123-37.
8. Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999;94:333-9.
9. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-100.
10. Issaad C, Ahmed M, Novault S, et al. Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7. Leukemia 2000;14:662-70.
11. Baron F, Turhan A, Giron-Michel J, et al. Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression. Blood 2002;99:2107-13.
12. Ljunggren H, Karre K. In search of the "missing self": MHC molecules and NK cell recognition. Immunol Today 1990;11:237-44.
13. Miller JS. Biology of natural killer cells in cancer and infection. Cancer Invest 2002;20:405-19.
14. Braud V, Allan D, O'Callaghan C, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998;391:795-9.
15. Leibson P. Cytotoxic lymphocyte recognition of HLA-E: utilizing a nonclassical window to peer into classical MHC. Immunity 1998;9:189-94.
16. Pessino A, Sivori S, Bottino C, et al. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med 1998;188:953-60.
17. Pende D, Parolini S, Pessino A, et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999;190:1505-16.
18. Lopez-Botet M, Bellon T. Natural killer cell activation and inhibition by receptors for MHC class I. Curr Opin Immunol 1999;11:301-7.
19. Cantoni C, Bottino C, Vitale M, et al. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med 1999;189:787-96.
20. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-9.
21. Cerwenka A, Bakker A, McClanahan T, et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 2000;12:721-7.
22. Carayol G, Robin C, Bourhis J, et al. NK cells differentiated from bone marrow, cord blood and peripheral blood stem cells exhibit similar phenotype and functions. Eur J Immunol 1998;28:1991-2000.
23. Malmberg K, Levitsky V, Norell H, et al. IFN-γ protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest 2002;110:1515-23.
24. Landolfo S, Guarini A, Riera L, et al. Chronic myeloid leukemia cells resistant to interferoji-α lack STAT1 expression. Hematol J 2000;1:7-14.
25. Lin T, Mahajan S, Frank D. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene 2000;19:2496-504.
26. Holtschke T, Lohler J, Kanno Y, et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 1996;18:307-17.
27. Schmidt M, Nagel S, Proba J, et al. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood 1998;91:22-9.
28. Schmidt M, Hochhaus A, Konig-Merediz S, et al. Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon α therapy. J Clin Oncol 2000;18:3331-8.
29. Schmidt M, Hochhaus A, Nitsche A, Hehlmann R, Neubauer A. Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-α. Blood 2001;97:3648-50.
30. Takaoka A, Mitani Y, Suemori H, et al. Cross-talk between interferon-γ and -α/β signaling components in caveolar membrane domains. 2000;288:2357-60.
31. Molldrem J, Lee P, Kant S, et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest 2003;111:639-47.
32. Burchert A, Wolfl S, Schmidt M, et al. Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 2003;101:259-64.